This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Feb 2013

Novartis names Dr Joerg Reinhardt as new chairman

Dr Joerg Reinhardt will be the new chairman of Novartis, succeeding Dr Daniel Vasella.

Novartis has revealed that Dr Joerg Reinhardt is set to become the company's new chairman following a period of transition.

Due to the departure of Dr Daniel Vasella, Dr Reinhardt will join the board of the Swiss pharmaceutical giant for a three-year term in August and has been designated to become chairman after his nomination was approved by shareholders.

In the interim period, current vice-chairman Prof Dr Ulrich Lehner has been selected to lead the board.
Dr Lehner said the firm was "losing a unique forward thinker of the industry and an extraordinarily successful business leader" with the departure of Dr Vasella.

The outgoing chairman, who was appointed in 1999 and has now been given an unpaid honorary chairman role at Novartis, wished Dr Reinhardt success in his new position.

Dr Vasella described his successor as "a very experienced healthcare executive with deep knowledge of the company and the industry", as well as praising his commitment to innovation.


Related News